Accéder au contenu
Merck
Toutes les photos(1)

Documents

K3502

Sigma-Aldrich

Anti-Human Kappa Light Chain (Bound and Free) antibody produced in goat

affinity isolated antibody, lyophilized powder

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Numéro MDL:
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.46

Source biologique

goat

Niveau de qualité

Conjugué

unconjugated

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

secondary antibodies

Clone

polyclonal

Forme

lyophilized powder

Technique(s)

quantitative precipitin assay: suitable

Température de stockage

2-8°C

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... IGK@(50802)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Anti-Human κ Light Chain (bound and free) antibody is obtained from goat antiserum. Immunospecific purification removes all goat serum proteins and immunoglobulins that do not bind to the κ light chain (bound and free). The antibody preparation is specific for κ light chains when tested against bound and free light chains. The product shows no reaction with bound or free λ light chains.

Immunogène

Purified human normal and myeloma κ light chain

Application

Anti-Human κ Light Chain (Bound and Free)-FITC antibody was used for as secondary antibody in ELISA at a working antibody dilution of 1:200 using maize seed extracts. For ELISA using NSO/1 myeloma cells, HEK293 cells and mouse plasma, antibody concentration of 1-2 μg/ml was used. The antibody was also used to coat the electrode surface in the preparation of antiatrazine immunosensor.
Anti-Human Kappa Light Chain (Bound and Free) antibody produced in goat has been used in western blotting.

Forme physique

Lyophilized from 0.01 M sodium phosphate, 0.015 M sodium chloride, pH 7.2

Reconstitution

Reconstitute with 0.135 M sodium chloride.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Outil de sélection de produits.


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Eva Gschmack et al.
Journal of neural transmission (Vienna, Austria : 1996), 129(5-6), 545-555 (2022-04-03)
Idiopathic Parkinson's disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus-subcoeruleus complex; (stage 2)
Characterization of immunological interactions at an immunoelectrode by scanning electron microscopy
Ambrosi A et al
Electroanalysis, 19, 244-252 (2007)
Yvonne J Rosenberg et al.
PloS one, 11(3), e0152760-e0152760 (2016-04-01)
Intravascular delivery of broadly neutralizing antibodies (bnAbs) has shown promise for prevention and treatment of HIV infection. However, multiple IV administrations in geographic locations with poor accessibility to medical care have practical limitations. We have assessed the efficacy of plant-derived
Koreen Ramessar et al.
Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3727-3732 (2008-03-05)
A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite
Sven Mathias et al.
Biotechnology and bioengineering, 117(1), 5-16 (2019-10-22)
Although most therapeutic monoclonal antibodies (mAbs) can routinely be produced in the multigram per litre range, some mAb candidates turn out to be difficult-to-express (DTE). In addition, the class of more complex biological formats is permanently increasing and mammalian expression

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique